Employing Late-Stage Functionalization Strategies to Address Metabolic Challenges in Drug Discovery

In the course of medicinal chemistry campaigns, issues related to drug metabolism frequently present significant challenges to progressing chemical series towards tool molecules or clinical candidates. Addressing these issues typically requires designing molecules with specific point-changes to test particular metabolism-related hypotheses. However, accessing these test molecules in a timely manner to inform future rounds of decision-making and design often presents a significant synthetic challenge. In this report, we present case studies showcasing the use of Minsici and direct metalation chemistries as part of a Late-Stage Functionalization strategy to address specific metabolic issues plaguing two medicinal chemistry programs. The success of these approaches allowed rapid access to new analogs with improved metabolic stability, and more importantly, key insights that informed on strategies to progress these chemical series towards valuable tool compounds.

Authors

Institutions

Publication Details

Journal
Synlett
Published
2026-10-13
DOI
https://doi.org/10.1055/a-2981-3437
Primary Topic
Coordination Chemistry and Organometallics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Employing Late-Stage Functionalization Strategies to Address Metabolic Challenges in Drug Discovery

Cheol Keun Chung, Derun Li, Amy Bittner McCracken, Shane W. Krska et al.
Synlett
Coordination Chemistry and Organometallics
article

Employing Late-Stage Functionalization Strategies to Address Metabolic Challenges in Drug Discovery

Cheol Keun Chung, Derun Li, Amy Bittner McCracken, Shane W. Krska, Petr Váchal, Huifang Yao, 李国庆, Melodie Christensen, Brian McKittrick, Kevin D. Dykstra, Scott B. Hoyt, David Hesk, Claire Lankin, Brandon Taoka, George Doss, Wendy Zhong, Kerry Fillgrove, Mikhail Reibarkh, Li Xiao, James Small, Shawn Walsh, Daniel DiRocco, Yong Liu, Eric Streckfuss
article en

Abstract

In the course of medicinal chemistry campaigns, issues related to drug metabolism frequently present significant challenges to progressing chemical series towards tool molecules or clinical candidates. Addressing these issues typically requires designing molecules with specific point-changes to test particular metabolism-related hypotheses. However, accessing these test molecules in a timely manner to inform future rounds of decision-making and design often presents a significant synthetic challenge. In this report, we present case studies showcasing the use of Minsici and direct metalation chemistries as part of a Late-Stage Functionalization strategy to address specific metabolic issues plaguing two medicinal chemistry programs. The success of these approaches allowed rapid access to new analogs with improved metabolic stability, and more importantly, key insights that informed on strategies to progress these chemical series towards valuable tool compounds.

Synlett
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Openalex Percentile: Top 25%
Coordination Chemistry and Organometallics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.